CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 70 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04467411
NCT04467411N/AActiveOn TrackUpdated 2mo ago

Randomised Controlled Study of Physical Exercise Intervention in Breast Cancer Patients at Risk of Anthracycline-induced Cardiomyopathy:The EMBRACE Study

University of Aberdeen·observational·Posted Jul 13, 2020·Updated Apr 30, 2026

In Brief

An observational study for Breast Cancer. Active but no longer recruiting, targeting 70 participants across 2 sites.

Detailed Summary

Cardiomyopathy is a condition that affects the heart muscle, whereby it becomes enlarged, thick or rigid. When the heart muscle becomes involved, it affects the pumping action of the heart. This condition can affect as many as 10% of all patients after undergoing anthracycline cancer drug therapy and unfortunately carries the worst prognosis of all cardiomyopathies. To date, there is no effective intervention that will prevent a patient from developing this condition. The research conducted will look to see if an energy imbalance in the heart predates the onset of detrimental changes to the pumping function of the heart, if this is detected then we can act earlier to prevent the pumping function deteriorating.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited Kingdom
Collaborators--

Timeline

N/AActive
20202021202220232024202520262027202820292030
First PostedJul 13, 2020
Enrollment StartFeb 1, 2020
Primary CompletionAug 30, 2030
TodayJul 2, 2026
Enrollment to primary: 10.6 yearsPosted 6.0 years agoPrimary completion in 4.2 years